Diomed Holdings, Inc. (AMEX: DIO), a leading developer and marketer of minimally-invasive medical technologies, including its patented EndoVenous Laser Treatment (EVLT®) for varicose veins, today announced that Mr. Jim Wylie, President and Chief Executive Officer of Diomed will be presenting an overview of the Company's business at the upcoming Roth Capital Partners 2007 New York Conference at the Westin New York at Times Square on Thursday, September 6, 2007 at 8:30 a.m. EST.
“We are pleased to participate in the ROTH 2007 New York Conference and we look forward to updating the investment community on our recent company performance and accomplishments,” commented James Wylie, Chief Executive Officer of Diomed Holdings, Inc.
To access the live audio broadcast or the subsequent archived recording, log onto: www.diomedinc.com. The archived recording will be available though September 20, 2007.
About Roth
Since 1984 Roth Capital Partners, LLC (“Roth”) has been a leader and innovator in the small and micro cap markets. Roth’s exclusive focus has been, is, and will continue to be providing the full spectrum of investment banking services, including raising capital, research coverage, creating liquidity, trading and market making, merger and acquisition advisory services, sales support, and investor conferences, to our customers.
The Roth Capital Partners 2007 New York Conference is recognized as one of the nation's leading institutional investor conferences for small and micro cap companies, the conference will feature presentations from more than 230 companies’ representative of the Technology, Healthcare, Financial Services and Consumer Products sectors
About Diomed
Diomed develops and commercializes minimal and micro-invasive medical procedures that use its proprietary laser technologies and disposable products. Diomed’s EVLT® laser vein ablation procedure is used in varicose vein treatments. Diomed also provides photodynamic therapy (PDT) for use in cancer treatments, and dental and general surgical applications. The EVLT® procedure and the Company’s related products were cleared by the United States FDA in January of 2002. Along with lasers and single-use procedure kits for its EVLT® laser vein treatment, the Company provides its customers with state of the art physician training and practice development support. Additional information is available on the Company’s website: www.evlt.com